1. Home
  2. DOUG vs ACOG Comparison

DOUG vs ACOG Comparison

Compare DOUG & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$1.81

Market Cap

178.2M

Sector

Real Estate

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$7.89

Market Cap

185.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
ACOG
Founded
1911
2000
Country
United States
Canada
Employees
N/A
71
Industry
Building operators
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
178.2M
185.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DOUG
ACOG
Price
$1.81
$7.89
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
435.4K
54.8K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
118.68
N/A
EPS
N/A
N/A
Revenue
$955,578,000.00
N/A
Revenue This Year
N/A
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$4.50
52 Week High
$3.19
$10.24

Technical Indicators

Market Signals
Indicator
DOUG
ACOG
Relative Strength Index (RSI) 47.89 61.97
Support Level $1.73 $5.11
Resistance Level $1.84 $8.80
Average True Range (ATR) 0.11 0.51
MACD -0.01 -0.02
Stochastic Oscillator 27.69 64.74

Price Performance

Historical Comparison
DOUG
ACOG

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: